Stephen Dodson of Bretton Fund presented his in-depth investment thesis on UnitedHealth Group (US: UNH) at Best Ideas 2026.
Thesis summary:
UNH operates as a dominant healthcare franchise combining UnitedHealthcare, the nation’s largest insurer, with Optum, a massive healthcare services arm serving 100 million Americans. This dual structure creates a distinct advantage, particularly in the shift toward Value-Based Care (VBC), where provider incentives align with patient outcomes to control costs. By owning both the insurance risk and the care delivery network (OptumHealth), the company leverages superior data and scale to drive efficiencies that pure-play competitors cannot match. The business has delivered consistent low-double-digit compounding in revenue and EPS, supported by high returns on capital and a diverse stream of profit pools across pharmacy benefits, data analytics, and care delivery.
The company recently faced substantial headwinds driven by a sharp, unexpected increase in healthcare utilization and an underwriting failure in its Medicare Advantage (MA) book. In 2025, the Medical Loss Ratio (MLR) spiked to near 90%, well above the historical average of 82%, as the company aggressively expanded into MA just as patient acuity and utilization rates accelerated. This mispricing was exacerbated by regulatory rate pressures and a lag effect from delayed COVID-19 treatments, leading to fears of permanently impaired earnings and causing the stock to trade at a discount relative to its history.
Stephen views these operational setbacks as cyclical and fixable rather than structural. Under the leadership of returning CEO Stephen Hemsley, management is aggressively repricing its book of business, increasing premiums on commercial plans by low double digits and ACA plans by roughly 25%. The company is also pruning unprofitable membership, projecting a loss of ~1 million MA subscribers to reset the cost base. While these actions will dampen near-term growth, they are designed to restore operating margins to the historical 8-9% range over the medium term, with the company expecting a return to regular growth by 2027.
Long-term growth remains underpinned by secular tailwinds, specifically the ongoing penetration of MA and the broader expansion of US health spending. As the industry transitions from fee-for-service to VBC—growing at 15% annually—UnitedHealth’s integrated model positions it to capture economics across the value chain. Optum’s diverse business lines, including OptumRx and OptumInsight, provide durability against volatility in the insurance underwriting cycle. Furthermore, the company maintains a shareholder-centric capital allocation strategy, consistently deploying free cash flow toward dividends and share repurchases, although buybacks have been temporarily paused to reduce leverage following the Amedisys acquisition.
Shares recently traded at roughly $341, implying a market capitalization of $310 billion and a 2.6% dividend yield. While the stock trades at approximately 21x depressed 2025 earnings of $16.32, the valuation compresses to roughly 16x estimated 2027 earnings of nearly $21 as margins recover. Stephen argues that the market is currently underwriting permanently lower margins of 5-6%, ignoring the high probability of a mean reversion to historical profitability levels. The current valuation offers a compelling entry point for a high-quality compounder temporarily dislocated by solvable underwriting errors.
Disclaimer
Best Ideas 2026 is held from January 6-23, 2026. The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.
Slides
Let’s take a closer look.
